From WisPolitics.com/WisBusiness.com …
— Accuray has entered a 10-year “master research agreement” with the UW School of Medicine and Public Health, aimed at further developing precision cancer therapies.
“By leveraging our respective strengths, we aim to extend the curative power of radiotherapy so departments of all sizes around the world can benefit from advanced adaptive therapies,” Accuray President and CEO Steve La Neve said in a statement.
The agreement builds on an existing relationship between UW-Madison and the company, whose first radiation platform called the TomoTherapy System was invented at the university by Prof. Thomas “Rock” Mackie in the late 1980s.
Since that time, the company says it’s boosted the system’s image quality and speed, along with other improvements.
Accuray also makes a radiation therapy device called the CyberKnife, which is used to treat both benign and malignant tumors using a robotic arm guided by an imaging system.
The new research effort covers clinical research, education and training, along with efforts to develop “adaptive therapies” to improve cancer treatment.
Prof. Zachary Morris, chair of human oncology for the UW SMPH, says the agreement will “accelerate the process of translating research innovation into technologies that better serve patients.”
See the release below.
Top Stories
– FDA’s top drug regulator ousted amid agency upheaval
– US health department withdraws vaccine advisory panel charter
– Medical Care Delays for Approval Persist, Despite Insurers’ Promises
– US bans foreign travelers from Ebola-impacted nations
– Ebola risk in US remains low amid Congo outbreak, CDC says
– Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs
Press Releases
– Emplify Health: Champions Mental Health Month with expanding services, community initiatives
